In the biotech world, return on investment is typically measured in trials completed, patents issued, and capital raised. But for Leen Kawas—scientist, entrepreneur, and CEO of EIT Pharma—the definition of ROI has always been broader. It includes the lives improved, the platforms built, the researchers funded, and the ripple effects of science moving from the bench to the bedside. Her work reflects a deeper conviction: innovation must be financially viable, but its true value lies in what it makes possible—for patients, practitioners, and future founders.

Kawas’s path has been defined by both scientific rigor and entrepreneurial risk. She first rose to prominence as co-founder and CEO of Athira Pharma, a company focused on neurodegenerative disease therapies. Under her leadership, Athira raised over $400 million and became one of the few female-founded biotech firms in the U.S. to go public. But that success, while measurable in investor returns, was never the endpoint. For Leen Kawas, IPOs and funding rounds are milestones—not finish lines. They provide the infrastructure for something else: impact at scale.

Now, as CEO of EIT Pharma and managing general partner at Propel Bio Partners, she brings that same philosophy to a broader portfolio of ventures. Inherent Biosciences, where she also serves on the board, exemplifies this dual lens. The company is focused on epigenetic diagnostics—a complex, early-stage field that could redefine how conditions like male infertility are understood and treated. The potential financial upside is substantial, but what excites Kawas is the possibility of expanding care for patients who’ve long been underserved by mainstream medicine.

This impact-forward mindset doesn’t mean ignoring the fundamentals. Kawas is a disciplined strategist. She’s known for translating complex science into actionable roadmaps, de-risking early-stage platforms, and guiding companies through regulatory and investor scrutiny. But even in those moments—especially in those moments—she pushes teams to ask: What will this work change, if it succeeds? The answers to that question help shape everything from clinical trial design to hiring plans to investor communications.

One of the frameworks Kawas uses to evaluate opportunity is what she calls multi-dimensional value. This includes not just financial return, but scientific differentiation, platform scalability, and unmet patient need. If a project scores high on all four, it’s a strong candidate. If it only meets one or two, even with strong investor interest, it may not be the right fit. This lens helps ensure that the companies she backs don’t just perform well—they matter.

Kawas also brings a distinctive perspective as an operator-turned-investor. At Propel Bio Partners, she’s not just evaluating pitch decks from a distance. She’s been in the seat. She understands the tradeoffs founders face, the weight of clinical timelines, the complexity of fundraising while managing teams. This allows her to offer not only capital, but context. Her approach is hands-on, but not prescriptive. She believes in supporting founders without reshaping their vision—a reflection of the trust she wished she’d received more consistently in her early days.

Part of Kawas’s impact philosophy involves ecosystem building. She’s committed to shifting biotech’s center of gravity away from a narrow definition of who gets funded, who gets mentored, and who leads. By actively supporting women and underrepresented founders, she’s helping build a more expansive innovation economy—one that reflects a wider set of life experiences, patient needs, and scientific approaches. For her, this isn’t about optics. It’s about unlocking better outcomes through more inclusive perspectives.

She also pushes for long-term thinking in an industry often driven by short-term catalysts. While many biotech companies are built around exit events—acquisition, IPO, licensing—Kawas encourages teams to stay focused on the end-user: the patient. When science is aligned with need, and strategy is aligned with integrity, she argues, financial outcomes will follow. But when those elements fall out of sync, even the best-capitalized ventures can falter.

In doing so, she’s challenging the industry to evolve. Biotech doesn’t have to choose between ambition and responsibility, speed and safety, capital and care. Kawas believes these can be reconciled—if leaders are willing to ask better questions and design better incentives.

That belief has shaped her approach to board governance as well. At Inherent Biosciences and other companies in her portfolio, she emphasizes transparency, cross-functional collaboration, and early alignment around both mission and metrics. These aren’t just checkboxes. They’re conditions for sustainable execution—especially in fields where the science is complex and the stakes are high.

In an industry driven by breakthroughs, Leen Kawas stands out for how she defines success. Her legacy won’t just be measured in market caps or FDA approvals. It will be measured in the kind of companies she builds, the kind of leaders she backs, and the kind of science she helps translate into meaningful change. Her model isn’t just about investing in the future. It’s about shaping it.

For Leen Kawas, ROI will always include returns—but it will also include reach. And in the biotech world she’s helping to shape, that kind of value is the most enduring of all.

Learn more about Leen Kawas in her in-depth interview with Billion Success.